Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) saw a large growth in short interest in July. As of July 15th, there was short interest totalling 307,100 shares, a growth of 1,706.5% from the June 30th total of 17,000 shares. Based on an average daily volume of 10,300 shares, the short-interest ratio is currently 29.8 days. Approximately 6.4% of the company’s shares are short sold.
Lumos Pharma Stock Up 4.9 %
NASDAQ:LUMO opened at $8.18 on Friday. The company has a fifty day moving average of $7.52 and a 200 day moving average of $8.40. Lumos Pharma has a 52 week low of $6.15 and a 52 week high of $11.52. The firm has a market capitalization of $68.46 million, a P/E ratio of -2.31 and a beta of 1.24.
Lumos Pharma (NASDAQ:LUMO – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.92) EPS for the quarter, meeting analysts’ consensus estimates of ($0.92). The firm had revenue of $0.11 million for the quarter. As a group, analysts anticipate that Lumos Pharma will post -3.93 EPS for the current year.
Wall Street Analyst Weigh In
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Urban Wealth Management LLC bought a new position in Lumos Pharma in the 2nd quarter worth $27,000. PVG Asset Management Corp bought a new position in Lumos Pharma in the 4th quarter worth $71,000. Envestnet Asset Management Inc. bought a new position in Lumos Pharma in the 4th quarter worth $72,000. Key Financial Inc bought a new position in Lumos Pharma in the 2nd quarter worth $84,000. Finally, Private Advisor Group LLC bought a new position in Lumos Pharma in the 1st quarter worth $263,000. 38.35% of the stock is currently owned by institutional investors.
Lumos Pharma Company Profile
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Wingstop And Hershey Are Two Food Stocks Overcoming Inflation
- Can International Business Machines Recover After Its Sell-Off?
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.